Brazil will sell 1 cannabis-based medicine

Medicament is used for treating symptoms associated with multiple sclerosis, but it is contraindicated for marijuana users.
16/01/2017 11h39 - Updated 16/01/2017 11h42
Photo: reproduction

The National Health Surveillance Agency (Anvisa) reported on Monday the first drug Cannabis sativa based, the plant that gives rise to marijuana, no Brasil.

Or specific drug Mevatyl (tetraidrocanabinol (THC), 27 mg / mL + cannabidiol (CBD), 25 mg / mL) It is manufactured by GW Pharma Limited - United Kingdom and distributed in Brazil by Beaufour Ipsen Pharmaceuticals Inc. in the form of spray.

The product is indicated for the treatment of "moderate to severe spasticity related to multiple sclerosis,", but it is contraindicated for pregnant women, elderly, people with epilepsy or marijuana users.

According to the technical note of the record, the effectiveness of the drug has been tested in clinical studies with over 1,5 thousand patients. The drug was approved in other 28 countries, which has the trade name Saltivex.

No Brasil, the Mevatyl will be marketed with a black stripe and your purchase will be subject to medical prescription.

In November last year, Anvisa facilitated the marketing of cannabidiol based medicines in Brazil by publishing a standard on the subject.

Second rule, laboratories can order derivatives record in concentration, no maximum, 30 THC mg per milliliter and 30 cannabidiol mg per milliliter. Products with higher concentration than that established in the country still banned.

The release of cannabinoids use in Brazil was determined by Anvisa in 2015, after a move made by relatives of patients, especially children who had repeated bouts of seizure.

Last November, the agency determined that new import requests for cannabidiol products are analyzed as a priority, since we submitted all the necessary documents required in the process.


*** If you are in favor of a totally free and impartial press, collaborate enjoying our page on Facebook and visiting often the AM POST.

Contact Terms of use